Mutual of America Capital Management LLC Lowers Stake in Boston Scientific Co. (NYSE:BSX)

Mutual of America Capital Management LLC decreased its position in shares of Boston Scientific Co. (NYSE:BSX) by 2.6% during the 4th quarter, according to its most recent disclosure with the SEC. The firm owned 176,947 shares of the medical equipment provider’s stock after selling 4,797 shares during the period. Mutual of America Capital Management LLC’s holdings in Boston Scientific were worth $15,805,000 as of its most recent SEC filing.

Other hedge funds have also recently bought and sold shares of the company. BNP PARIBAS ASSET MANAGEMENT Holding S.A. lifted its stake in shares of Boston Scientific by 4.4% during the 3rd quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 4,119,399 shares of the medical equipment provider’s stock worth $345,205,000 after purchasing an additional 173,034 shares during the period. Mechanics Bank Trust Department acquired a new position in Boston Scientific in the fourth quarter valued at $415,000. Highland Capital Management LLC purchased a new position in Boston Scientific during the fourth quarter worth about $4,887,000. Covenant Asset Management LLC acquired a new stake in Boston Scientific in the 4th quarter worth about $3,405,000. Finally, Brookstone Capital Management grew its holdings in Boston Scientific by 23.7% in the 4th quarter. Brookstone Capital Management now owns 105,860 shares of the medical equipment provider’s stock valued at $9,455,000 after buying an additional 20,307 shares during the period. Institutional investors and hedge funds own 89.07% of the company’s stock.

Boston Scientific Trading Up 3.2 %

NYSE BSX opened at $104.02 on Friday. The stock has a market cap of $153.51 billion, a P/E ratio of 83.21, a PEG ratio of 2.79 and a beta of 0.80. The company’s fifty day simple moving average is $99.28 and its 200-day simple moving average is $90.22. The company has a current ratio of 1.08, a quick ratio of 1.02 and a debt-to-equity ratio of 0.41. Boston Scientific Co. has a 52 week low of $65.52 and a 52 week high of $107.17.

Boston Scientific (NYSE:BSX) last issued its quarterly earnings data on Wednesday, February 5th. The medical equipment provider reported $0.70 EPS for the quarter, topping analysts’ consensus estimates of $0.65 by $0.05. Boston Scientific had a net margin of 11.07% and a return on equity of 17.80%. Equities research analysts predict that Boston Scientific Co. will post 2.85 EPS for the current fiscal year.

Analysts Set New Price Targets

Several brokerages have recently weighed in on BSX. Stifel Nicolaus increased their price objective on shares of Boston Scientific from $100.00 to $115.00 and gave the stock a “buy” rating in a report on Thursday, February 6th. Needham & Company LLC reaffirmed a “hold” rating on shares of Boston Scientific in a research note on Thursday, February 6th. Deutsche Bank Aktiengesellschaft raised shares of Boston Scientific from a “hold” rating to a “buy” rating and set a $108.00 price objective for the company in a research note on Friday, January 10th. JPMorgan Chase & Co. increased their target price on Boston Scientific from $100.00 to $110.00 and gave the stock an “overweight” rating in a research report on Monday, December 16th. Finally, Wells Fargo & Company boosted their price target on Boston Scientific from $100.00 to $118.00 and gave the company an “overweight” rating in a research report on Thursday, February 6th. One analyst has rated the stock with a hold rating, twenty-two have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Buy” and an average target price of $108.91.

Insider Activity at Boston Scientific

In other news, EVP John Bradley Sorenson sold 1,201 shares of the business’s stock in a transaction dated Friday, February 14th. The shares were sold at an average price of $106.31, for a total value of $127,678.31. Following the completion of the sale, the executive vice president now owns 25,443 shares of the company’s stock, valued at approximately $2,704,845.33. The trade was a 4.51 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Wendy Carruthers sold 6,983 shares of the company’s stock in a transaction dated Monday, December 2nd. The shares were sold at an average price of $90.78, for a total transaction of $633,916.74. Following the completion of the sale, the executive vice president now owns 29,308 shares in the company, valued at approximately $2,660,580.24. This trade represents a 19.24 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 144,305 shares of company stock valued at $14,954,985. Insiders own 0.50% of the company’s stock.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.